Relay Therapeutics, Inc.

RLAYSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1812364

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$25.5M	$1.4M	$3.0M	$82.7M	$82.7M
Research and Development Expense	—	—	—	—	—
Operating Expenses	$398.5M	$300.7M	$367.7M	$138.4M	$84.0M
Operating Income (Loss)	-$373.0M	-$299.3M	-$364.7M	-$55.8M	-$84.0M
Other Nonoperating Income (Expense)	$31.0M	$8.8M	$826.0K	$3.4M	$8.7M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$342.0M	-$290.5M	-$363.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$871.3M	$844.0M	$1.1B	$1.0B	$799.8M
Assets, Current	$809.2M	$770.1M	$1.0B	$976.2M	$770.1M
Cash and Cash Equivalents, at Carrying Value	$124.3M	$143.7M	$151.8M	$447.6M	$42.0M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$306.0K	$403.0K	$75.0M
Liabilities	$93.5M	$92.0M	$149.6M	$110.6M	$36.5M
Liabilities, Current	$50.7M	$30.3M	$63.7M	$24.3M	$13.6M
Accounts Payable, Current	$14.1M	$9.2M	$10.6M	$8.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$300.3M	-$229.5M	-$74.4M	-$102.5M	-$66.1M
Net Cash Provided by (Used in) Investing Activities	$257.6M	-$188.7M	-$479.5M	$81.7M	-$319.0M
Net Cash Provided by (Used in) Financing Activities	$34.8M	$289.9M	$388.1M	$426.5M	$5.6M
Payments to Acquire Property, Plant, and Equipment	$4.1M	$9.1M	$3.5M	$1.9M	$8.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)